A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism

Ipilimumab is a monoclonal antibody targeting the cytotoxic T-lymphocyte antigen-4 receptor, which was originally approved for the treatment of metastatic melanoma. It is the first immune checkpoint inhibitor to enter clinical practice. Immune toxicity due to ipilimumab causing colitis, hepatitis, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Erra, Amani, Pannu, Bibek Singh, Patel, Sabah, Qureshi, Faisal, Soliman, Mohanad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713251/
https://www.ncbi.nlm.nih.gov/pubmed/31497432
http://dx.doi.org/10.7759/cureus.5001
_version_ 1783446845884727296
author Erra, Amani
Pannu, Bibek Singh
Patel, Sabah
Qureshi, Faisal
Soliman, Mohanad
author_facet Erra, Amani
Pannu, Bibek Singh
Patel, Sabah
Qureshi, Faisal
Soliman, Mohanad
author_sort Erra, Amani
collection PubMed
description Ipilimumab is a monoclonal antibody targeting the cytotoxic T-lymphocyte antigen-4 receptor, which was originally approved for the treatment of metastatic melanoma. It is the first immune checkpoint inhibitor to enter clinical practice. Immune toxicity due to ipilimumab causing colitis, hepatitis, and dermatitis are well-described in literature. We report a case of hypophysitis resolving with corticosteroid treatment, following which the patient developed long-term primary thyroid impairment. This highlights the importance of vigilance for rarer immune-related toxicities as clinical utilization of ipilimumab becomes more widespread.
format Online
Article
Text
id pubmed-6713251
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-67132512019-09-06 A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism Erra, Amani Pannu, Bibek Singh Patel, Sabah Qureshi, Faisal Soliman, Mohanad Cureus Endocrinology/Diabetes/Metabolism Ipilimumab is a monoclonal antibody targeting the cytotoxic T-lymphocyte antigen-4 receptor, which was originally approved for the treatment of metastatic melanoma. It is the first immune checkpoint inhibitor to enter clinical practice. Immune toxicity due to ipilimumab causing colitis, hepatitis, and dermatitis are well-described in literature. We report a case of hypophysitis resolving with corticosteroid treatment, following which the patient developed long-term primary thyroid impairment. This highlights the importance of vigilance for rarer immune-related toxicities as clinical utilization of ipilimumab becomes more widespread. Cureus 2019-06-25 /pmc/articles/PMC6713251/ /pubmed/31497432 http://dx.doi.org/10.7759/cureus.5001 Text en Copyright © 2019, Erra et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Erra, Amani
Pannu, Bibek Singh
Patel, Sabah
Qureshi, Faisal
Soliman, Mohanad
A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
title A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
title_full A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
title_fullStr A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
title_full_unstemmed A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
title_short A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
title_sort rare case of ipilimumab-induced reversible hypophysitis and permanent primary hypothyroidism
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713251/
https://www.ncbi.nlm.nih.gov/pubmed/31497432
http://dx.doi.org/10.7759/cureus.5001
work_keys_str_mv AT erraamani ararecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT pannubibeksingh ararecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT patelsabah ararecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT qureshifaisal ararecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT solimanmohanad ararecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT erraamani rarecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT pannubibeksingh rarecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT patelsabah rarecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT qureshifaisal rarecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism
AT solimanmohanad rarecaseofipilimumabinducedreversiblehypophysitisandpermanentprimaryhypothyroidism

Ejemplares similares